Template:SubstanceBox/Buprenorphine: Difference between revisions
>Josikins Created page with "{{SubstanceBox <!-- Table Properties --> |MaterialTable_MaxWidth=345px |MaterialTable_Title={{PAGENAME}} <!-- Modules --> |ModuleSource=false |Module..." |
>Isaak Make insufflated route expanded by default. |
||
(22 intermediate revisions by 12 users not shown) | |||
Line 1: | Line 1: | ||
{{SubstanceBox | {{SubstanceBox | ||
<!-- | <!-- Special Parameters --> | ||
|MaterialTable_MaxWidth= | |displayClasses={{{displayClasses|}}} | ||
|MaterialTable_MaxWidth=250px | |||
|MaterialTable_Title={{PAGENAME}} | |MaterialTable_Title={{PAGENAME}} | ||
Line 10: | Line 11: | ||
|ModuleStructure=true | |ModuleStructure=true | ||
|ModuleNomenclature=true | |ModuleNomenclature=true | ||
|ModuleClassMembership=true | |||
|ModuleROA=true | |ModuleROA=true | ||
Line 31: | Line 33: | ||
<!-- Structure --> | <!-- Structure --> | ||
|MolecularStructureCaption= | |MolecularStructureCaption=Molecular structure of buprenorphine | ||
|SkeletalImageFile=File: | |SkeletalImageFile=File:Buprenorphine.svg | ||
|SkeletalImageWidth= | |SkeletalImageWidth=245px | ||
|3DImageFile= | |3DImageFile= | ||
|3DImageWidth= | |3DImageWidth=200px | ||
<!-- Nomenclature --> | <!-- Nomenclature --> | ||
|NameCommon=Buprenex, Subutex, Butrans, Cizdol | |NameCommon=[[common name::Buprenex]], [[common name::Subutex]], [[common name::Butrans]], [[common name::Cizdol]], [[common name::Addnok]], [[common name::Transtec]] | ||
|NameSubstitution= | |NameSubstitution= | ||
|NameSystematic=(2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol | |NameSystematic=(2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylbutan-2-ol | ||
<!-- Class Membership --> | |||
|EffectClass=[[psychoactive class::Opioid]] | |||
|ChemicalClass=[[chemical class::Morphinan]] | |||
<!-- Dosage/Duration --> | <!-- Dosage/Duration --> | ||
|InsufflatedROA=true | |InsufflatedROA=true | ||
|InsufflatedROA_Collapsed= | |InsufflatedROA_Collapsed=false | ||
|InsufflatedROA_Caption= | |InsufflatedROA_Caption= | ||
|InsufflatedROA_Bioavailability=48%<ref name="Eriksen1989">{{cite journal | vauthors=((Eriksen, J.)), ((Jensen, N. H.)), ((Kamp-Jensen, M.)), ((Bjarnø, H.)), ((Friis, P.)), ((Brewster, D.)) | journal=The Journal of Pharmacy and Pharmacology | title=The systemic availability of buprenorphine administered by nasal spray | volume=41 | issue=11 | pages=803–805 | date= November 1989 | issn=0022-3573 | doi=10.1111/j.2042-7158.1989.tb06374.x}}</ref> | |||
|InsufflatedROA_Threshold=<0.2 mg | |InsufflatedROA_Threshold=< [[Insufflated threshold dose::0.2]] [[Insufflated dose units::mg]] | ||
|InsufflatedROA_Light=0.2 - 0.4 mg | |InsufflatedROA_Light=[[Insufflated min light dose::0.2]] - [[Insufflated max light dose::0.4]] mg | ||
|InsufflatedROA_Common=0.4 - 0.8 mg | |InsufflatedROA_Common=[[Insufflated min common dose::0.4]] - [[Insufflated max common dose::0.8]] mg | ||
|InsufflatedROA_Strong=0.8 - 1.5 mg | |InsufflatedROA_Strong=[[Insufflated min strong dose::0.8]] - [[Insufflated max strong dose::1.5]] mg | ||
|InsufflatedROA_Heavy= | |InsufflatedROA_Heavy=[[Insufflated heavy dose::1.5]] mg + | ||
|InsufflatedROA_TimelineFile= | |InsufflatedROA_TimelineFile= | ||
|InsufflatedROA_TimelineWidth= | |InsufflatedROA_TimelineWidth= | ||
|InsufflatedROA_Duration=8-14 | |InsufflatedROA_Duration=[[Insufflated min total time::8]] - [[Insufflated max total time::14]] [[Insufflated total time units::hours]] | ||
|InsufflatedROA_Onset=30-60 minutes | |InsufflatedROA_Onset=[[Insufflated min onset time::30]] - [[Insufflated max onset time::60]] [[Insufflated onset time units::minutes]] | ||
|InsufflatedROA_Peak=4-8 hours | |InsufflatedROA_Peak=[[Insufflated min peak time::4]] - [[Insufflated max peak time::8]] [[Insufflated peak time units::hours]] | ||
|InsufflatedROA_Offset= | |InsufflatedROA_Offset= | ||
|InsufflatedROA_Aftereffects=1-3 days | |InsufflatedROA_Aftereffects=[[Insufflated min afterglow time::1]] - [[Insufflated max afterglow time::3]] [[Insufflated afterglow time units::days]] | ||
|SublingualROA=true | |SublingualROA=true | ||
|SublingualROA_Collapsed=true | |SublingualROA_Collapsed=true | ||
|SublingualROA_Caption= | |SublingualROA_Caption= | ||
|SublingualROA_Bioavailability= 30%<ref name="Mendelson1997">{{cite journal | vauthors=((Mendelson, J.)), ((Upton, R. A.)), ((Everhart, E. T.)), ((Jacob, P.)), ((Jones, R. T.)) | journal=Journal of Clinical Pharmacology | title=Bioavailability of sublingual buprenorphine | volume=37 | issue=1 | pages=31–37 | date= January 1997 | issn=0091-2700 | doi=10.1177/009127009703700106}}</ref> | |||
|SublingualROA_Threshold=<=[[Sublingual threshold dose::0.3]] [[Sublingual dose units::mg]] | |||
|SublingualROA_Light= | |SublingualROA_Light=[[Sublingual min light dose::1]] - [[Sublingual max light dose::2]] mg | ||
|SublingualROA_Common= | |SublingualROA_Common=[[Sublingual min common dose::2]] - [[Sublingual max common dose::4]] mg | ||
|SublingualROA_Strong= | |SublingualROA_Strong=[[Sublingual min strong dose::4]] - [[Sublingual max strong dose::8]] mg | ||
|SublingualROA_Heavy= | |SublingualROA_Heavy=[[Sublingual heavy dose::8]]mg + | ||
|SublingualROA_TimelineFile= | |SublingualROA_TimelineFile= | ||
|SublingualROA_TimelineWidth= | |SublingualROA_TimelineWidth= | ||
|SublingualROA_Duration= | |SublingualROA_Duration=[[Sublingual min total time::18]] - [[Sublingual max total time::24]] [[Sublingual total time units::hours]] | ||
|SublingualROA_Onset=40-80 minutes | |SublingualROA_Onset=[[Sublingual min onset time::40]] - [[Sublingual max onset time::80]] [[Sublingual onset time units::minutes]] | ||
|SublingualROA_Peak= | |SublingualROA_Peak=[[Sublingual min peak time::1.5]] - [[Sublingual max peak time::2]] [[Sublingual peak time units::hours]] | ||
|SublingualROA_Aftereffects=1-3 days | |SublingualROA_Aftereffects=[[Sublingual min afterglow time::1]] - [[Sublingual max afterglow time::3]] [[Sublingual afterglow time units::days]] | ||
}} | }} |